BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Aljaafari MN, AlAli AO, Baqais L, Alqubaisy M, AlAli M, Molouki A, Ong-Abdullah J, Abushelaibi A, Lai KS, Lim SE. An Overview of the Potential Therapeutic Applications of Essential Oils. Molecules 2021;26:628. [PMID: 33530290 DOI: 10.3390/molecules26030628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee T. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther 2018;47:1673-81. [DOI: 10.1111/apt.14682] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
3 Badii VS, Buabeng KO, Agyarko Poku T, Forkuo AD, Boamah BB, Arhin SM, Kpewou DE. Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults. Int J Chronic Dis 2018;2018:3702740. [PMID: 29850480 DOI: 10.1155/2018/3702740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bielen R, Robaeys G, Schelfhout S, Monbaliu D, Van der Merwe S, Pirenne J, Nevens F. Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study. Transpl Int 2018;31:503-9. [PMID: 29359868 DOI: 10.1111/tri.13112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
6 Lim SS, Liao HT, Tsai CY. Telbivudine associated mitochondrial myopathy. Liver Int 2018;38:1139. [PMID: 29570939 DOI: 10.1111/liv.13742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Fujii T, Takase KI, Honda H, Kawamura N, Yamasaki R, Urata M, Uchiumi T, Iwaki T, Kira JI. Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study. Neuropathology 2019;39:162-7. [PMID: 30847961 DOI: 10.1111/neup.12548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu D, Liu L, Wang L, Duan S, Song Y, Qu M, Gao N, Wu J, Zhang H, Wu H, Kong W, Yu B, Yu X. Therapeutic effects of mesenchymal stem cells combined with short hairpin RNA on liver injury induced by hepatitis B virus infection. Mol Med Rep. 2018;17:1731-1741. [PMID: 29257255 DOI: 10.3892/mmr.2017.8096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Pilli S, Lip PL. Reversible retinal toxicity in early oral Entecavir therapy for hepatitis-B infection. Eye (Lond) 2018;32:1792-4. [PMID: 29934633 DOI: 10.1038/s41433-018-0156-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kim SS, Ahn EK, Cho SY, Park RW, Cho HJ, Kim JH, Kim HG, Lee GR, Hwang SH, Yang MJ, Cheong JY, Cho SW. Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e11087. [PMID: 29901622 DOI: 10.1097/MD.0000000000011087] [Reference Citation Analysis]
11 Fischer MG, Newman W, Hammer K, Rohrich M, Lo TS. Comparison of Renal Function Between Tenofovir Disoproxil Fumarate and Other Nucleos(t)ide Reverse Transcriptase Inhibitors in Patients With Hepatitis B Virus Infection. Fed Pract 2021;38:363-7. [PMID: 34733088 DOI: 10.12788/fp.0169] [Reference Citation Analysis]
12 Lin X, Song A, Zheng S, Chen X. Respiratory failure as the prominent manifestation of entecavir-associated mitochondrial myopathy: a case report. BMC Infect Dis 2022;22:188. [PMID: 35209862 DOI: 10.1186/s12879-022-07159-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
14 Dönmüş B, Ünal S, Kirmizitaş FC, Türkoğlu Laçin N. Virus-associated ribozymes and nano carriers against COVID-19. Artif Cells Nanomed Biotechnol 2021;49:204-18. [PMID: 33645342 DOI: 10.1080/21691401.2021.1890103] [Reference Citation Analysis]
15 Innocenti I, Morelli F, Autore F, Corbingi A, Pasquale R, Sorà F, Pompili M, Laurenti L. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. Leuk Lymphoma 2019;60:1340-2. [PMID: 30730231 DOI: 10.1080/10428194.2018.1523401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Ribeiro AI, Dias AM, Zille A. Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review. ACS Appl Nano Mater 2022;5:3030-64. [DOI: 10.1021/acsanm.1c03891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
17 Xu K, Liu LM, Farazi PA, Wang H, Rochling FA, Watanabe-Galloway S, Zhang JJ. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action 2018;11:1433987. [PMID: 29447614 DOI: 10.1080/16549716.2018.1433987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
19 Lim J, Lee JB, An J, Song GW, Kim KM, Lee HC, Shim JH. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study. J Viral Hepat 2022. [PMID: 35718999 DOI: 10.1111/jvh.13721] [Reference Citation Analysis]
20 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Tsukune Y, Sasaki M, Komatsu N. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers (Basel) 2019;11:E1819. [PMID: 31752356 DOI: 10.3390/cancers11111819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ledoux N. Hepatitis B and Acute Liver Failure. Critical Care Nursing Clinics of North America 2022. [DOI: 10.1016/j.cnc.2022.04.012] [Reference Citation Analysis]
23 Othumpangat S, Noti JD. Antiviral Drugs. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2018. pp. 345-61. [DOI: 10.1016/bs.seda.2018.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Kammarabutr J, Mahalapbutr P, Okumura H, Wolschann P, Rungrotmongkol T. Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase. J Biomol Struct Dyn 2021;39:2502-11. [PMID: 32308149 DOI: 10.1080/07391102.2020.1751715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Zhang YT, Liu J, Pan XB, Gao YD, Hu YF, Lin L, Cheng HJ, Chen GY. Successful treatment of infantile hepatitis B with lamivudine: A case report. World J Clin Cases 2021; 9(14): 3442-3448 [PMID: 34002156 DOI: 10.12998/wjcc.v9.i14.3442] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yang SS, Cai CW, Ma XQ, Xu J, Yu CB. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int 2020;19:507-14. [PMID: 33051132 DOI: 10.1016/j.hbpd.2020.09.007] [Reference Citation Analysis]
27 Zareifopoulos N, Lagadinou M, Karela A, Kyriakopoulou O, Velissaris D. Neuropsychiatric Effects of Antiviral Drugs. Cureus 2020;12:e9536. [PMID: 32905132 DOI: 10.7759/cureus.9536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]